Quintrio
Home

ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

Iridex Corp

IRIX

IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.674 – $0.812
Volume 16,740
Market cap $12M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$12.12M
Price / earnings
—
Price / book
3.33×
Price / sales
0.24×
EV / sales
0.22×
EV / EBITDA
-4.82×

Profitability

Earnings per share
-$0.20
Return on assets
-13.01%
Return on equity
-97.47%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.04×
Current ratio
1.82×
Quick ratio
1.08×
Cash ratio
0.36×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$2M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for IRIX, quarterly periods
Line itemQ2 FY2026 Jul 4, 2026Q1 FY2026 Apr 4, 2026Q4 FY2025 Jan 3, 2026Q3 FY2025 Sep 27, 2025Q2 FY2025 Jun 28, 2025Q1 FY2025 Mar 29, 2025Q4 FY2024 Dec 28, 2024Q3 FY2024 Sep 28, 2024
Revenue$12.57M$11.8M$14.72M$12.48M$13.57M$11.9M$12.7M$11.58M
Cost of revenue$8.27M$7.06M$9.25M$8.47M$8.89M$6.84M$7.11M$7.26M
Gross profit$4.3M$4.74M$5.48M$4.01M$4.68M$5.06M$5.59M$4.32M
Selling, general and administrative$4.39M$4.16M$4.54M$4.45M$4.75M$4.38M$4.98M$4.89M
Research and development$936K$905K$949K$972K$871K$876K$1.11M$1.3M
Total operating expenses$5.33M$5.07M$5.49M$5.42M$5.62M$5.26M$6.09M$6.19M
Operating income-$1.03M-$324K-$15K-$1.41M-$940K-$205K-$502K-$1.87M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$1.2M-$466K-$164K-$1.57M-$973K-$1.67M-$840K-$1.92M
Income taxes$70K$58K$20K$4K$21K$12K-$6K$17K
Net income-$1.27M-$524K-$184K-$1.57M-$994K-$1.69M-$834K-$1.93M
Net income attributable to common shareholders-$1.27M-$524K-$184K-$1.57M-$994K-$1.69M-$834K-$1.93M
EBITDA-$943K-$224K$136K-$1.3M-$813K-$70K-$367K-$1.73M
Basic earnings per share-$0.07-$0.03-$0.01-$0.09-$0.06-$0.10-$0.05-$0.12
Diluted earnings per share-$0.07-$0.03-$0.01-$0.09-$0.06-$0.10-$0.05-$0.12

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma

Iridex Corporation announced the publication of a two-year clinical study in the International Journal of Ophthalmology demonstrating that MicroPulse transscleral laser therapy (TLT) significantly reduces intraocular pressure and medication burden in patients with early to advanced glaucoma. The study of 84 eyes showed mean IOP reduction from 22.32 mmHg to 14.05 mmHg, with 86% success rate in POAG patients and 81% in PACG patients, with no reported complications or visual acuity reductions.

GlobeNewswire Inc.

Iridex Announces Plans to Relocate Headquarters

Iridex Corporation announced its intent to relocate its headquarters from Mountain View, California to San Jose, California. The company signed a non-binding letter of intent for a 31,000 square feet location on January 26, 2026, expecting to generate approximately $0.4 million in savings for fiscal year 2026 and $0.6 million in annualized savings thereafter. The relocation is part of the company's ongoing cost reduction strategy while maintaining operations and talent attraction in the Bay Area.

The Motley Fool

Iridex Reports 7 Percent Q2 Revenue Gain

Medical device company Iridex reported Q2 2025 results with modest revenue growth, narrower net loss, and positive adjusted EBITDA, driven by cost control and operational discipline.

GlobeNewswire Inc.

Iridex Comments on Recent Stock Price Volatility

Iridex Corporation, a leader in laser-based medical systems for ophthalmology, commented on recent stock price volatility, stating that there have been no material changes to its operating or financial condition.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.